Cancer Research AACR Legacy  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 28, 475-480, March 1, 1968]
© 1968 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gibson, J. E.
Right arrow Articles by Becker, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gibson, J. E.
Right arrow Articles by Becker, B. A.

The Teratogenicity of Cyclophosphamide in Mice1 ,2

James E. Gibson3 and Bernard A. Becker

Department of Pharmacology, Oakdale Toxicology Center, University of Iowa College of Medicine, Iowa City, Iowa 52240

Cyclophosphamide, administered intraperitoneally to time-dated pregnant Swiss Webster mice on gestational Days 9 through 14 in a dosage of 20 mg/kg, resulted in increased numbers of resorptions and a variety of teratogenic effects. Gross examination of fetuses revealed cleft palate, exencephaly, digital defects, and kinky tail. Skeletal anomalies included polydactyly, syndactyly, ectrodactyly, adactyly, fusion of the long bones, curvature of the long bones, and missing ribs. Soft tissue malformations included open eyes, aphakia, microphakia, hydronephrosis, and hydrocephalus. Dosages of 5 and 10 mg/kg resulted in increased resorption and decreased growth rates in a dose-related manner but produced no discernible anomalies. Fetal mortality curves were biphasic, with the highest peak occurring on administration Days 9 and 10 and a second peak on Days 13 and 14.

1 This research was supported by NIH Grant No. GM-12675.

2 A preliminary report of this work was presented at the Sixth Annual Meeting of the Society of Toxicology, Atlanta, Georgia, March 23–25, 1967.

3 USPHS Trainee, NIH Training Grant GM-1308.

Received 7/14/67. Accepted 11/ 4/67.




This article has been cited by other articles:


Home page
Hum ReprodHome page
S. Tartakover Matalon, A. Ornoy, A. Fishman, L. Drucker, and M. Lishner
The effect of 6-mercaptopurine on early human placental explants
Hum. Reprod., May 1, 2005; 20(5): 1390 - 1397.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
S. Moallem and B. Hales
The role of p53 and cell death by apoptosis and necrosis in 4-hydroperoxycyclophosphamide-induced limb malformations
Development, January 8, 1998; 125(16): 3225 - 3234.
[Abstract] [PDF]


Home page
International Journal of ToxicologyHome page
R.L. Schuler, M.A. Radike, B.D. Hardin, and R.W. Niemeier
Pattern of Response of Intact Drosophila to Known Teratogens
International Journal of Toxicology, January 1, 1985; 4(4): 291 - 303.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
P. S. SCHEIN and S. H. WINOKUR
Immunosuppressive and Cytotoxic Chemotherapy: Long-Term Complications
Ann Intern Med, January 1, 1975; 82(1): 84 - 95.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1968 by the American Association for Cancer Research.